Announcements
- Abeona Therapeutics Provides Regulatory Update on Pz-cel
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
- Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Announces $50 Million Credit Facility
- Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
- Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
- Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
More ▼
Key statistics
On Tuesday, Abeona Therapeutics Inc (PCJ:DUS) closed at 3.10, 8.39% above its post-IPO low of 2.86, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.10 |
---|---|
High | 3.10 |
Low | 3.10 |
Bid | 3.80 |
Offer | 3.96 |
Previous close | 2.96 |
Average volume | 110.00 |
---|---|
Shares outstanding | 27.36m |
Free float | 25.41m |
P/E (TTM) | -- |
Market cap | 94.10m USD |
EPS (TTM) | -2.59 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 07:12 BST.
More ▼